TGFB2 and non-small cell lung carcinoma: Furthermore, a phase II trial for belagenpumatucel-L, a vaccine produced from NSCLC cells transfected with TGF-β2 AON, has shown beneficial effects on survival without any significant adverse effects; phase III studies in lung cancer patients are ongoing [31].